

## **Hyalose, L.L.C. Chief Scientist Awarded OCAST OARS Grant**

Oklahoma City, OK, Austin, TX—July 18, 2005 – Emergent Technologies Inc. (ETI), announced today that a Chief Scientist of its portfolio company, Hyalose, L.L.C., Dr. Paul DeAngelis, has been awarded a grant of \$277,200 from the Oklahoma Center for Advancement of Science and Technology, OCAST, to develop Hyaluronan-assisted targeting systems for drug delivery.

The award will be made to Dr. DeAngelis's University of Oklahoma Health Sciences Center lab and shared with Hyalose's lab located at the Oklahoma Health Center Research Park in Oklahoma City.

Of the 69 applications for the OCAST Oklahoma Applied Research Support (OARS) R&D Funding Competition, Dr. DeAngelis's proposal was among 11 which were approved. "Scientific research is a leading factor in developing our economy. We continuously look for ways to fund Oklahoma research", stated Steve Biggers, director of Research and Development division at OCAST.

"We are delighted that OCAST continues to support Dr. DeAngelis in his research, and Hyalose is similarly pleased to match the award," stated Tommy Harlan, CEO of ETI. John Hoopingarner, COO, added, "This funding will enable Dr. DeAngelis and Hyalose to create drug conjugates consisting of hyaluronan oligosaccharides linked to chemo drugs which will create a relatively non-toxic and soluble prodrug that will bind selectively to receptors on the surface of a cancer cell thus improving the effectiveness of existing drugs for single and combination therapies by lowering toxicity and increasing effectiveness."

Hyalose has already established several research and business collaborations with several major corporate and academic partners worldwide. Visit its website at [www.hyalose.com](http://www.hyalose.com). Hyalose was founded in 2000 by ETI which is an Austin, Texas-based venture capital firm that specializes in forming, funding, commercializing, and managing biotech companies for the purpose of converting institutional and university-based technology into high return ventures. Visit its website at [www.emergentechnologies.com](http://www.emergentechnologies.com)

Contact: John Hoopingarner  
2508 Ashley Worth Blvd., Suite 200  
Austin, TX 78738  
(T) 512 263-3232 (F) 512 263-3236

KEYWORD: Oklahoma City, Austin

INDUSTRY KEYWORD: Cancer, hyaluronan, targeting prodrug, chemotherapy, biodelivery